Clinical trial for Epithelial Ovarian Cancer
Official title AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
ClinicalTrials.gov ID: NCT07218809
What this study is testing
What is AZD5335?
AZD5335 is an investigational antibody drug conjugate being studied as a potential treatment for epithelial ovarian cancer. is designed to attach to specific targets on cancer cells and deliver a chemotherapy drug directly to them.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find out if AZD5335 helps women live longer without their cancer growing compared to current standard treatments.
- Who it's for
- The study is looking for women with high-grade ovarian, fallopian tube, or primary peritoneal cancer that has returned or grown despite prior platinum-based chemotherapy.
- What's involved
- Participants will receive either AZD5335 or a standard treatment (mirvetuximab soravtansine or chemotherapy) and undergo regular tests to monitor how the cancer is responding.
- Time commitment
- The study continues until the cancer grows or the participant stops taking part, requiring regular visits for check-ups and tests.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Key Participants with confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer.
- Participants who have only had one prior line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response...
- Participants who have received 2 or 3 lines of platinum therapy must have progressed ≤ 6 months after the date of the last dose of platinum.
- Participants must have radiologically progressed on or after their most recent line of therapy.
- Participants must have received at least one, but no more than 3, prior systemic lines of anti-cancer therapy, and for whom single-agent therapy is...
You likely can't join if
- Participants with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumours containing any of the above histologies, or low-grade...
- Primary platinum-refractory disease, defined as disease that did not respond to or has progressed ≤ 3 months after the last dose of first line...
- Participants with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing...
- Current signs, symptoms, or clinical investigations consistent with bowel obstruction, including sub-occlusive disease.
- Participant has non-infectious ILD/pneumonitis or has a history of non-infectious ILD/pneumonitis that required oral or IV steroids or supplemental...
- Prior treatment with any FRα-targeted therapy, including MIRV, or any TOP1i ADC.
See the full eligibility criteria
- Key Participants with confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer.
- Participants who have only had one prior line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response (CR or PR) and then progressed between \> 3 months and ≤ 6 months after...
- Participants who have received 2 or 3 lines of platinum therapy must have progressed ≤ 6 months after the date of the last dose of platinum.
- Participants must have radiologically progressed on or after their most recent line of therapy.
- Participants must have received at least one, but no more than 3, prior systemic lines of anti-cancer therapy, and for whom single-agent therapy is appropriate as the next line of treatment
- Participants with documented BRCA mutation (germline and/or somatic) must have received prior PARPi if the participant is eligible per approved label and standard-of-care institutional guidelines, except in cases of...
- Provision of an FFPE tumour tissue sample Key
- Participants with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumours containing any of the above histologies, or low-grade or borderline ovarian tumour.
- Primary platinum-refractory disease, defined as disease that did not respond to or has progressed ≤ 3 months after the last dose of first line platinum-containing chemotherapy.
- Participants with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring
- Current signs, symptoms, or clinical investigations consistent with bowel obstruction, including sub-occlusive disease.
- Participant has non-infectious ILD/pneumonitis or has a history of non-infectious ILD/pneumonitis that required oral or IV steroids or supplemental oxygen, or where suspected ILD/pneumonitis cannot be ruled out by...
- Prior treatment with any FRα-targeted therapy, including MIRV, or any TOP1i ADC.
- Major surgical procedure within 4 weeks of the first dose of study intervention
The study team makes the final eligibility decision.
Where it is enrolling
- Birmingham, Alabama, United States
- Washington D.C., District of Columbia, United States
- Gainesville, Florida, United States
- Jupiter, Florida, United States
- Miami, Florida, United States
- Peoria, Illinois, United States
- Urbana, Illinois, United States
- Fort Wayne, Indiana, United States
- Indianapolis, Indiana, United States
- Louisville, Kentucky, United States
- Towson, Maryland, United States
- Burlington, Massachusetts, United States
- Minneapolis, Minnesota, United States
- Springfield, Missouri, United States
- Billings, Montana, United States
- Omaha, Nebraska, United States
- Las Vegas, Nevada, United States
- Chapel Hill, North Carolina, United States
- Blue Ash, Ohio, United States
- Dayton, Ohio, United States
+ 67 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Birmingham, Alabama, United States; Washington D.C., District of Columbia, United States; Gainesville, Florida, United States; Jupiter, Florida, United States; Miami, Florida, United States; Peoria, Illinois, United States and 81 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.